In the fiscal year of 2014, the National Health Security Office (NHSO) started to disburse its budget based on the Quality and Outcomes Framework (QOF). The QOF is a budget allocation mechanism that incentivizes hospitals to provide quality primary care and achieve results based on the defined indic

Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary. Adding cetuximab to chemothera

In many countries, rotavirus vaccination is the most cost-effective way to prevent rotavirus diarrhea. With this in mind, the Essential Medicines and Technology Division (EMTD) in collaboration with Health Intervention Technology Assessment Program (HITAP), Mahidol Oxford Research Unit (MORU), and P

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and represents a significant global health concern. Infectious agents can be easily spread through respiratory droplets, and TB patients face a significant risk of mortality. The traditional sputum-based TB

Australia developed the Life-Saving Drugs Program (LSDP) in 1995 to complement the Pharmaceutical Benefits Scheme (PBS), expanding access to high-cost drugs for rare diseases (DRD). This program, funded and administered by the Department of Health and Aged Care, permitted sponsors (often pharmaceuti

The Cancer Drug Fund (CDF) is a dedicated source of funding in England for increasing patient access to high-cost cancer drugs, with a fixed budget of £340 million per year, operating since 2016. The CDF follows the appraisal by the National Institute of Health and Care Excellence (NICE) whic

The drug, linaclotide, will be sold under the brand name Linzess and carry a boxed warning that it should not be used in patients 16 or younger, the agency said.An estimated 63 million people suffer from chronic constipation, according to the National Institutes of Health. Additionally, an estimated

CHICAGO — Taking periodic breaks from a commonly used treatment for prostate cancer could shorten men’s lives, researchers reported here on SaturdayIn a large study, intermittent hormonal therapy proved to be less effective than continuous therapy for certain men with metastatic prostate cancer.The

Doctors often order tests and recommend drugs or procedures when they shouldn’t — sometimes even when they know they shouldn’t. The problem has become so serious that such groups as the American College of Physicians, the ABIM Foundation, the National Physicians Alliance and a coalition of medical s